Last updated 13 days ago

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

325 patients around the world
Available in Puerto Rico, Mexico, United States
The study has two parts which enroll separately from each other such that participants may choose to participate in either but not both: the main study and a study addendum. - The main study includes a 3-month, randomized, double-blind treatment period in which participants receive either galcanezumab or placebo, followed by a 9-month open-label extension in which all participants receive galcanezumab. - The study addendum is a stand-alone study of galcanezumab pharmacokinetics and safety in a group of participants separate from those in the main study. The study addendum includes a 5-month evaluation period after a single injection of galcanezumab, followed by a 9-month open-label extension.
Eli Lilly and Company
6Research sites
325Patients around the world
This study is for people with
Migraine
Requirements for the patient
To 17 Years
All Gender
Medical requirements
Sites
Centro de Investigación Médica Aguascalientes - CIMA
Centro de Investigación Médica Aguascalientes - CIMA
Recruiting
Av Independencia 2130, Trojes de Alonso, Aguascalientes
Unidad de Investigación en Salud
Recruiting
Trasviña y Retes No.1317 Col. San Felipe, Chihuahua
Hospital Infantil de México Federico Gómez
Recruiting
Calle Doctor Márquez 162 Delegación:, Doctores, Cuauhtémoc, 06720 Ciudad de México
Hospital Civil de Guadalajara Fray Antonio Alcalde
Recruiting
Guadalajara, Jalisco, Mexico, 44280
Panamerican Clinical Research S.A. de C.V
Recruiting
Guadalajara, 44670
Clínica de Enfermedades Crónicas y de Procedimientos Especiales - CECYPE
Recruiting
C. Nicolás Bravo 1734, Villa Universidad, 58060 Morelia, Mich., Mexico
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy